Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (271-280 of 377) with videos related to

Pageof 38
Sort By:
Geburtshilfe Und Frauenheilkunde|July 29, 2022
Update Breast Cancer 2022 Part 2 - Advanced Stage Breast CancerVolkmar Müller, Manfred Welslau, Diana Lüftner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2020
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer TrialThomas Karn, Tobias Meissner, Karsten E Weber, et al.
The Lancet. Oncology|March 1, 2011
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialLuca Gianni, Urania Dafni, Richard D Gelber, et al.
Breast Care (Basel, Switzerland)|November 12, 2015
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German ExpertsChristian Jackisch, Nadia Harbeck, Jens Huober, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2019
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancerJens Huober, Eileen Holmes, José Baselga, et al.
NPJ Breast Cancer|November 12, 2021
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightnessOtto Metzger-Filho, Katharine Collier, Sarah Asad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2025
Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA StudyPeter A Fasching, Sabine Schmatloch, Jan Hauke, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2021
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, et al.
BMC Cancer|November 12, 2020
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in GermanyHanna Huebner, Christian M Kurbacher, Geoffrey Kuesters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto StudyPeter A Fasching, Sibylle Loibl, Chunling Hu, et al.
Pageof 38

Showing results (271-280 of 377) with videos related to

Sort By:
Pageof 38
Geburtshilfe Und Frauenheilkunde|July 29, 2022
Update Breast Cancer 2022 Part 2 - Advanced Stage Breast CancerVolkmar Müller, Manfred Welslau, Diana Lüftner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2020
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer TrialThomas Karn, Tobias Meissner, Karsten E Weber, et al.
The Lancet. Oncology|March 1, 2011
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialLuca Gianni, Urania Dafni, Richard D Gelber, et al.
Breast Care (Basel, Switzerland)|November 12, 2015
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German ExpertsChristian Jackisch, Nadia Harbeck, Jens Huober, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2019
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancerJens Huober, Eileen Holmes, José Baselga, et al.
NPJ Breast Cancer|November 12, 2021
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightnessOtto Metzger-Filho, Katharine Collier, Sarah Asad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2025
Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA StudyPeter A Fasching, Sabine Schmatloch, Jan Hauke, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2021
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, et al.
BMC Cancer|November 12, 2020
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in GermanyHanna Huebner, Christian M Kurbacher, Geoffrey Kuesters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto StudyPeter A Fasching, Sibylle Loibl, Chunling Hu, et al.
Pageof 38